The first million doses of the new Flu-M vaccine by the Saint Petersburg SRI of Vaccines and Serums of the FMBA of Russia have been delivered to consumers.
On August 6, 2019, SPbSRIVS brought the first million doses of its new Flu-M flu vaccine to the market.
“As part of the preclinical trial, it was proved that the Flu-M vaccine forms a long-lasting immunity to all strains of the influenza virus, while there are no proven differences in the main indicators of effectiveness as compared to the best foreign analogues, in other words, the Flu-M vaccine is the first Russian-made world-class influenza vaccine manufactured using a unique technology without preservatives and immunomodulators,” said the SPbSRIVS Director Viktor Trukhin.
Today, influenza remains one of the most burning issues of modern public health, and amounts to the top 10 global threats according to experts of the World Health Organization (WHO).
As the developer and manufacturer of influenza vaccines of the Flu-M brand, SPbSRIVS is the Russia’s only influenza vaccine producer to be a member of the IFPMA IVS working group.
Remarkably, the current antigen of the influenza strain, constituting the Flu-M vaccine, was used by the essential WHO laboratory (NIBSC) to produce the standard antigen (the so-called standard), and was assigned the reference number 19/154.
This testifies to the high quality of the SPbSRIVS products that meet both international and WHO reference standards. The state-of-the-art technologies, confirmed by GMP certification, corporate culture, highly qualified personnel and well-balanced management decisions have also contributed to the breakthrough of the enterprise in St. Petersburg.
